THALES
9.6.2020 08:02:10 CEST | Business Wire | Press release
New insights from the 2020 Thales Data Threat Report – European Edition reveal that European organisations have a false sense of security when it comes to protecting themselves, with only two-thirds (68%) seeing themselves as vulnerable, down from nine in ten (86%) in 2018. This confidence flies in the face of the findings of the survey of 509 European executives which reveals over half (52%) of organisations were breached or failed a compliance audit in 2019, raising concerns as to why a fifth (20%) intend to reduce data security spend in the next year. The findings come as workers across Europe are working from home due to COVID-19, often using personal devices which don’t have the built-in security office systems do, significantly increasing risk to sensitive data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005431/en/
Thales will host a webinar, “Data Security Threats and Trends in Europe” on 16 June to discuss the report in more detail. To join, please visit the registration page .
Across the board, companies are racing to digitally transform and move more applications and data to the cloud; two-fifths (37%) of European countries stated they are aggressively disrupting the markets they participate in or embedding digital capabilities to enable greater enterprise agility. A key aspect of this transformation is in the cloud becoming the leading data environment. Nearly half (46%) of all data stored by European organisations is now stored in the cloud, and with 43% of that data in the cloud being described as sensitive, it is essential that it is kept safe.
As more sensitive data is stored in cloud environments, however, data security risks increase. This is of particular concern given that 100% of businesses surveyed report that at least some of the sensitive data they are storing in the cloud is not encrypted. Only 54% of sensitive data in the cloud is protected by encryption and even less (44%) is protected by tokenisation, highlighting the disconnect between the level of investment companies are making into cybersecurity and the increasing threats they face.
Multi-Cloud Adoption Complicates Data Security
Despite the multitude of threats, businesses feel that the complexity (40%) of their environments is holding their data security capabilities back. Multi-cloud adoption is the main driver of this complexity; four-fifths (80%) of businesses are using more than one IaaS (Infrastructure as a Service) vendor, whilst a third (29%) have more than 50 SaaS (Software as a Service) applications to manage. Businesses also identified a lack of budget (30%), staff to manage (28%) and organisation buy-in/low priority (25%) as other top blockers.
“Businesses are continuing to race towards digital transformation and many are increasingly reliant on complex cloud environments, without taking a zero-trust approach. Data is more at risk than ever, whilst organisations are unwittingly creating the perfect storm for hackers by not implementing the security basics,” commented Rob Elliss, EMEA Vice President for Data Security solutions at Thales . “Unfortunately, this will result in increasing problems, particularly in a world where working remotely will be part of the new-normal, unless companies can step up to the plate when it comes to keeping data safe.”
Quantum(fying) the problem
Whilst organisations continue to look at the threat of today, many are starting to turn their attention to peril that the acceleration of computing power, quantum, could bring to them. In fact, almost all (93%) respondents are concerned quantum computing will lead to exploits being created that could expose the sensitive data they hold. What’s more, seven in 10 (69%) European organisations expect quantum to affect their cryptographic operations in the next five years.
As a result, most organisations are reacting, with a third (31%) planning to offset quantum computing threats by switching away from static encryption or symmetric cryptography. Furthermore, a similar amount (30%) plans to implement key management that supports quantum safe random number generator.
“It is clear that businesses are aware of evolving threats they face and it’s reassuring to see them acknowledging some of the key steps they need to take – including moving away from static encryption and implementing quantum-proof key management. It’s critical, though, that organisations don’t just look at threats years away, but invest in their cybersecurity processes now and see it as an integral part of their digital transformation,” Elliss concluded .
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Market page
Download HD photos
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005431/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
